- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02440581
Renal Osteodystrophy: An Individual Management Approach
Renal Osteodystrophy: A Fresh Approach
Renal osteodystrophy (ROD) represents the bone histologic abnormalities resulting from loss of renal function. It starts early during the loss of kidney function and is seen in virtually all chronic end stage kidney disease patients on dialysis (CKD-5D). A major component of ROD is bone loss leading to chronic kidney disease (CKD) associated osteoporosis. Debilitating hip fractures occur in patients with CKD at a rate 4.4 times higher than in the general population, with associated high costs, morbidity and an annual mortality of 64%. CKD osteoporosis is distinctly different from post-menopausal osteoporosis. Presently, no uniformly accepted CKD osteoporosis treatment protocol exists because of challenges related to racially specific bone turnover states. Therefore, most physicians are reluctant to treat this disorder despite the profound impact on health and quality of life, and its association with vascular calcifications. These vascular calcifications confer an increased risk for cardiovascular events which are the major cause of the over 20% annual mortality rate in CKD-5D patients.
The goal of the proposed controlled randomized study is to test the concept that CKD osteoporosis can be successfully treated when treatment is individualized by patients' turnover status. The study will demonstrate that reversal of bone loss can be achieved by increasing bone formation in low turnover patients, and by reducing bone resorption in normal or high turnover patients. A second aim of this study is to provide new information whether these treatments will also retard progression of vascular calcifications. Blood tests measuring FGF23, indicators of Wnt pathway activity, bone resorption and formation will be followed to understand potential mechanisms and to evaluate their usefulness for prediction of changes in bone mass and vascular calcifications.
CKD-5D patients with established osteoporosis will be enrolled into one of two treatment arms based on bone turnover status. Each arm will be adaptively randomized by race, age and gender into treatment or control groups. In the low turnover arm, teriparatide combined with cinacalcet will be given, and in the normal or high turnover arm, alendronate will be administered. Bone mineral density will be measured at baseline and after one year of treatment by quantitative computed tomography. Calcifications of the coronaries, aorta and heart valves will also be measured at the same times by multi-detector computed tomography.
If this proof-of-concept study is successful, it will offer a heretofore unavailable treatment for osteoporosis in CKD-5D patients thus changing the prevailing clinical practice paradigm. This will provide immediate benefit to CKD patients by reducing fracture risk, bone pain, and cardiovascular risk, while greatly improving their quality of life. These improvements will also convey major socioeconomic benefits by decreasing the high associated treatment costs. The proposed study is highly relevant to the National Institute of Diabetes and Digestive and Kidney Diseases' mission of disseminating science-based information to improve the health and quality of life for patients with endocrine, metabolic and kidney diseases.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536
- University of Kentucky
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged 21 years or older;
- Chronic maintenance dialysis of at least 3 months' duration;
- Osteoporotic by DXA of either spine or total hip (Women: post-menopausal or age ≥ 50 with T-score ≤ -2.5; Men: age ≥ 50 with T-score ≤ -2.5; All others, Z-score ≤ -2.5);
- Mental competence;
- Willingness to participate in the study;
- Normal serum calcium.
Exclusion Criteria:
- Pregnancy or breast feeding;
- Incarceration;
- Systemic illnesses or organ diseases that may affect bone (except type 1 or type 2 diabetes mellitus);
- Clinical condition that may limit study participation (e.g., unstable angina, respiratory distress, infections).
- Chronic alcoholism and/or drug addiction;
- Known Paget 's disease of bone;
- Prior external beam or implant radiation therapy involving the skeleton;
- More than 3 computed tomography (CT) scans in the prior 12 months (to avoid excessive radiation exposure);
- Participation in a study of an investigational drug during the past 90 days;
- Planning to move out of the area within 1 year of the study;
- On active transplant list;
- BMD t-score of the radius less than -3.5 by DXA (to avoid the known potential negative effects of teriparatide treatment on BMD of the radius);
- Planned or anticipated oral surgery within the next 12 months;
- Inability to stand or sit upright for at least 30 minutes;
- Abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia;
- Treatment within last 6 months with drugs that may affect bone metabolism including bisphosphonates and teriparatide (except for treatment with calcitriol, vitamin D analogs and/or calcimimetics);
- Current treatment with medicines containing digoxin or warfarin;
- Calcidiol level below the normal range. (The current routine clinical practice in our dialysis clinics is to check calcidiol status twice yearly and supplement with vitamin D according to serum calcidiol levels. It is therefore unlikely that a substantial number of patients will be excluded due to this exclusion criterion.)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control, low turnover
No intervention in low turnover osteoporosis control group.
|
|
Experimental: Treatment, low turnover
Low turnover osteoporosis group treated with teriparatide and cinacalcet.
|
|
No Intervention: Control, high turnover
No intervention in high turnover osteoporosis control group.
|
|
Experimental: Treatment, high turnover
High turnover osteoporosis group treated with alendronate.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Quantitative Computed Tomography (QCT) Bone Mineral Density of the Hip
Time Frame: One Year (at baseline and one year)
|
At one year the investigators will asses bone mass using QCT of the total hip and compare one year changes in bone mass between the treatment and control groups.
|
One Year (at baseline and one year)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Coronary Artery Calcifications by Multiple Detector Computed Tomography (MDCT)
Time Frame: One year (at baseline and one year)
|
At one year the investigators will asses differences between the treatment and control groups in changes in Coronary Artery Calcifications by MDCT. 1 Yr.
Change in Sqrt CAC Vol.
|
One year (at baseline and one year)
|
Change in Serum Biochemical Bone Markers of Bone Activity - Parathyroid Hormone (PTH)
Time Frame: 1 Year (at baseline and one year)
|
Bone markers of bone activity tracked over time for changes.1 Yr.
Change in PTH
|
1 Year (at baseline and one year)
|
Change in Serum Biochemical Bone Markers of Bone Activity - Bone-specific Alkaline Phosphatase (BSAP)
Time Frame: 1 year (at baseline and one year)
|
Bone markers of bone activity tracked over time for changes.1 Yr.
Change in BSAP
|
1 year (at baseline and one year)
|
Change in Serum Biochemical Bone Markers of Bone Activity - Fibroblast Growth Factor 23 (FGF23)
Time Frame: 1 Year (at baseline and 1 year)
|
Bone markers of bone activity tracked over time for changes. 1 Yr.
Change in FGF-23
|
1 Year (at baseline and 1 year)
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Kidney Diseases
- Urologic Diseases
- Endocrine System Diseases
- Nutrition Disorders
- Musculoskeletal Diseases
- Parathyroid Diseases
- Avitaminosis
- Deficiency Diseases
- Malnutrition
- Bone Diseases
- Renal Insufficiency, Chronic
- Bone Diseases, Metabolic
- Calcium Metabolism Disorders
- Rickets
- Vitamin D Deficiency
- Hyperparathyroidism, Secondary
- Hyperparathyroidism
- Kidney Failure, Chronic
- Renal Insufficiency
- Chronic Kidney Disease-Mineral and Bone Disorder
- Physiological Effects of Drugs
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormone Antagonists
- Bone Density Conservation Agents
- Calcium-Regulating Hormones and Agents
- Calcimimetic Agents
- Alendronate
- Teriparatide
- Cinacalcet
Other Study ID Numbers
- 14-0976-F6A
- R01DK080770 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Failure, Chronic
-
Centre Hospitalier Universitaire DijonTerminatedEnd-stage Chronic Kidney FailureFrance
-
Baxter Healthcare CorporationRecruitingAcute Kidney Failure | Chronic Kidney FailureChina
-
Angiodynamics, Inc.TerminatedChronic Kidney Disease | Acute Kidney Injury | Acute Renal Failure | Renal Failure Chronic Contrast InducedUnited States
-
Texas A&M UniversityWithdrawnChronic Kidney FailureUnited States
-
Hopital Jean MinjozUnknownCardiac Surgical Procedures | Preoperative KIDNEY FAILURE, CHRONIC | Postoperative KIDNEY FAILURE, ACUTEFrance
-
University of WashingtonJohns Hopkins University; National Institute of Diabetes and Digestive and... and other collaboratorsRecruitingChronic Kidney Diseases | Acute Renal Failure | Acute Renal Injury | Acute Kidney Failure | Chronic Renal Insufficiency | Kidney Failure, Acute | Renal Insufficiency, Acute | Acute Renal Insufficiency | Acute Kidney Insufficiency | Renal Failure, Acute | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney... and other conditionsUnited States
-
Nantes University HospitalNot yet recruiting
-
Ozge AKBABAAtaturk UniversityCompletedChronic Kidney FailureTurkey
-
Chinese PLA General HospitalCompletedKidney Failure,ChronicChina
-
Fatma Alzahraa Mohamed Ibrahim Hassan HaggagUnknown
Clinical Trials on Cinacalcet
-
University Hospital, RouenInstitut National de la Santé Et de la Recherche Médicale, FranceCompletedParathyroid Hormone Suppression Test With CinacalcetFrance
-
AmgenCompletedSecondary Hyperparathyroidism, Chronic Kidney DiseaseUnited States, Czechia, Germany, France, Hungary, Greece, Belgium, Italy, Poland, Russian Federation, Ukraine
-
AmgenCompletedSecondary Hyperparathyroidism
-
AmgenCompletedCardiovascular Disease | Hyperparathyroidism | End Stage Renal Disease | Chronic Kidney Disease | Secondary Hyperparathyroidism | Chronic Renal Failure | Coronary Artery Calcification | Vascular Calcification | Kidney Disease | Calcification | Nephrology
-
Kyowa Kirin Co., Ltd.CompletedPrimary Hyperparathyroidism | Parathyroid Carcinoma | HypercalcemiaJapan
-
AmgenCompletedEnd Stage Renal Disease | Secondary Hyperparathyroidism
-
AmgenCompletedSecondary HyperparathyroidismUnited States, Italy, Belgium, Switzerland, Hungary, Spain, Turkey, Poland, Portugal, United Kingdom, Czech Republic, Macedonia, The Former Yugoslav Republic of
-
Tufts UniversityCompleted
-
Seoul National University HospitalJeil-Kirin Pharmaceutical Inc.CompletedSecondary HyperparathyroidismKorea, Republic of
-
AmgenCompleted